Baird raised the firm’s price target on LivaNova (LIVN) to $75 from $70 and keeps an Outperform rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees “several potential paths to improved” share performance for the group in 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN:
- LivaNova receives increased CMS reimbursement for VNS Therapy
- LivaNova price target raised to $70 from $65 at Mizuho
- LivaNova price target raised to $70 from $63 at Baird
- LivaNova’s Strategic Growth Plan and OSA Device Commercialization Justify Buy Rating
- LivaNova expects OSA business to be break-even by 2029